Colleen represents emerging high-growth companies throughout their life cycle, with a focus on all aspects of emerging company development – including corporate formation, venture capital financings, corporate spinouts and restructurings, mergers & acquisitions, and capital markets transactions. She also has experience representing venture capital and angel investors in their investment transactions. Since 2021, Colleen has handled VC financings with an aggregate deal value of more than $1 billion. Colleen is counsel to companies and their investors in a broad range of industries on a global basis, with a focus on the biotechnology, medical device, digital health and software sectors.
